B
66.16
-0.35 (-0.53%)
| Penutupan Terdahulu | 66.51 |
| Buka | 66.05 |
| Jumlah Dagangan | 3,317,017 |
| Purata Dagangan (3B) | 1,726,274 |
| Modal Pasaran | 12,608,972,800 |
| Harga / Pendapatan (P/E TTM) | 39.86 |
| Harga / Pendapatan (P/E Ke hadapan) | 16.84 |
| Harga / Jualan (P/S) | 4.55 |
| Harga / Buku (P/B) | 2.29 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 Feb 2025 - 24 Feb 2025 |
| Margin Keuntungan | 11.71% |
| Margin Operasi (TTM) | 15.27% |
| EPS Cair (TTM) | 1.66 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 28.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 162.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.13% |
| Nisbah Semasa (MRQ) | 4.27 |
| Aliran Tunai Operasi (OCF TTM) | 414.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 144.67 M |
| Pulangan Atas Aset (ROA TTM) | 3.00% |
| Pulangan Atas Ekuiti (ROE TTM) | 6.25% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | BioMarin Pharmaceutical Inc. | Menurun | Menurun |
AISkor Stockmoo
0.4
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | 0.38 |
|
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 0.87% |
| % Dimiliki oleh Institusi | 97.63% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 109.00 (JP Morgan, 64.75%) | Beli |
| Median | 86.00 (29.99%) | |
| Rendah | 65.00 (Baird, -1.75%) | Pegang |
| Purata | 89.09 (34.66%) | |
| Jumlah | 7 Beli, 4 Pegang | |
| Harga Purata @ Panggilan | 66.89 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 12 Dec 2024 | 90.00 (36.03%) | Beli | 66.26 |
| 30 Oct 2024 | 90.00 (36.03%) | Beli | 66.68 | |
| Wolfe Research | 15 Nov 2024 | 95.00 (43.59%) | Beli | 63.42 |
| Baird | 30 Oct 2024 | 65.00 (-1.75%) | Pegang | 66.68 |
| Canaccord Genuity | 30 Oct 2024 | 84.00 (26.96%) | Pegang | 66.68 |
| Citigroup | 30 Oct 2024 | 81.00 (22.43%) | Pegang | 66.68 |
| Evercore ISI Group | 30 Oct 2024 | 105.00 (58.71%) | Beli | 66.68 |
| JP Morgan | 30 Oct 2024 | 109.00 (64.75%) | Beli | 66.68 |
| RBC Capital | 30 Oct 2024 | 80.00 (20.92%) | Pegang | 66.68 |
| 04 Oct 2024 | 80.00 (20.92%) | Pegang | 69.51 | |
| UBS | 30 Oct 2024 | 106.00 (60.22%) | Beli | 66.68 |
| Raymond James | 10 Oct 2024 | 79.00 (19.41%) | Beli | 69.85 |
| Barclays | 04 Oct 2024 | 86.00 (29.99%) | Beli | 69.51 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |